These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22586572)

  • 1. Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress.
    Garcia VM; Cassier PA; de Bono J
    Cancer Discov; 2011 Aug; 1(3):207-12. PubMed ID: 22586572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From darkness to light with biomarkers in early clinical trials of cancer drugs.
    Carden CP; Banerji U; Kaye SB; Workman P; de Bono JS
    Clin Pharmacol Ther; 2009 Feb; 85(2):131-3. PubMed ID: 19151637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How can attrition rates be reduced in cancer drug discovery?
    Moreno L; Pearson AD
    Expert Opin Drug Discov; 2013 Apr; 8(4):363-8. PubMed ID: 23373702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
    Carden CP; Sarker D; Postel-Vinay S; Yap TA; Attard G; Banerji U; Garrett MD; Thomas GV; Workman P; Kaye SB; de Bono JS
    Drug Discov Today; 2010 Feb; 15(3-4):88-97. PubMed ID: 19961955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New science-based endpoints to accelerate oncology drug development.
    Kelloff GJ; Sigman CC
    Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers in early cancer drug development: limited utility.
    Glassman RH; Ratain MJ
    Clin Pharmacol Ther; 2009 Feb; 85(2):134-5. PubMed ID: 19151638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker-driven patient selection for early clinical trials.
    Dienstmann R; Rodon J; Tabernero J
    Curr Opin Oncol; 2013 May; 25(3):305-12. PubMed ID: 23493192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic biomarkers for molecular cancer therapeutics.
    Sarker D; Workman P
    Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early oncology clinical trial design in the era of molecular-targeted agents.
    Brunetto AT; Kristeleit RS; de Bono JS
    Future Oncol; 2010 Aug; 6(8):1339-52. PubMed ID: 20799878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers of cell death applicable to early clinical trials.
    Dean E; Greystoke A; Ranson M; Dive C
    Exp Cell Res; 2012 Jul; 318(11):1252-9. PubMed ID: 22483936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials and biomarker development with molecularly targeted agents and radiotherapy.
    Dhani N; Siu LL
    Cancer Metastasis Rev; 2008 Sep; 27(3):339-49. PubMed ID: 18379730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic biomarkers: falling short of the mark?
    Gainor JF; Longo DL; Chabner BA
    Clin Cancer Res; 2014 May; 20(10):2587-94. PubMed ID: 24831281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
    Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Front-line drug discovery system for cancer].
    Mizukami T
    Gan To Kagaku Ryoho; 2008 Dec; 35(13):2293-300. PubMed ID: 19098393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of anti-cancer drugs.
    Arrondeau J; Gan HK; Razak AR; Paoletti X; Le Tourneau C
    Discov Med; 2010 Oct; 10(53):355-62. PubMed ID: 21034677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.